Kashiv Finishes Patient Recruitment In Late Stage Xolair Biosimilar Trial
After Starting In October 2023, The Trial Has Now Concluded Enrollment
Following on from its recently announced US licensing deal with Amneal over its Xolair biosimilar, Kashiv has finished patient recruitment for a trial for the omalizumab candidate, paving the way for submissions.
